CMH Multan Institute of Medical Sciences

Cardiotoxicity and safety of zanubrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: a real-world retrospective cohort study using the TriNetX registry

Abstract Background Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults in the Western countries. Ibrutinib, a first-generation Bruton’s tyrosine kinase (BTK) inhibitor, is commonly used for relapsed/refractory CLL but is associated with cardiovascular adv...

Blinatumomab versus chemotherapy in pediatric B-ALL: A meta-analysis of randomized trials in relapsed and high-risk frontline disease

BACKGROUND: B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, comprising almost 25 % of childhood malignancies. Despite advances in chemotherapy, relapse remains a major cause of treatment failure, particularly in high-risk patients. Blinatumomab, a...